Molecular Biology Of Varicella Zoster Virus Infection
$40,704ZIAFY2025AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 38690731Paper 33259596Paper 31159224Paper 30568636Paper 29599765Paper 29046461Paper 28637759Paper 27188665Paper 27078099Paper 26482341Paper 25916342Paper 25798530Paper 24990909Paper 24606682Paper 24227856Paper 24171531Paper 23863052Paper 23192871Paper 22238304Paper 21515789Paper 21159875Paper 20593027Paper 20225013Paper 20225012Paper 20116820Paper 19368500Paper 19233447Paper 18971269Paper 18277922Paper 17553876Paper 17507475Paper 17151102Paper 17055432Paper 15913699Paper 15890936Paper 15795292Paper 15385676Paper 15193381Paper 14564000Paper 14512565Paper 12627493Paper 12551972Paper 12502838Paper 11884583Paper 11339555Paper 11162819
Abstract
Varicella-zoster virus (VZV) establishes latency in human sensory and cranial nerve ganglia during primary infection (varicella), and the virus can reactivate and cause zoster after primary infection. At present, one varicella vaccine and one zoster vaccine are licensed and available for use in the United States. We have been collaborating with Christopher Pleyer in the National Heart Lung and Blood Institute to look at the response of patients with hematologic malignancies to the zoster subunit vaccine.
View original record on NIH RePORTER →